Dr Meric-Bernstam talks to ecancer at ASCO 2023 about data she presented on trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate.

Encouraging responses and long-lasting clinical benefit in several tumour types was observed in the phase II DESTINY-PanTumor02 study.

Treatment achieved an objective response rate of 61.3% with a median duration of response of 22.1 months in patients with the highest levels of HER2 expression.

Across all patients, the overall response rate (ORR) was 37.1% with a median DOR of 11.8 months. An ORR of more than 30% was observed in all cancer types except biliary tract (22%) and pancreatic cancers (4%).

Across different disease sites, trastuzumab deruxtecan resulted in the following ORRs:

Endometrial cancer: 57.5% for all patients, 84.6% for IHC 3+, and 47.1% for IHC 2+
Cervical cancer: 50% for all patients, 75% for IHC 3+, 40% for IHC 2+
Ovarian cancer: 45% for all patients, 63.6% for IHC 3+, 36.8% for IHC 2+
Urothelial cancer: 39% for all patients, 56.3% for IHC 3+, 35% for IHC 2+
Biliary tract cancer: 22% for all patients, 56.3% for IHC 3+, 0% for IHC 2+
Pancreatic cancer: 4% for all patients, 0% for IHC 3+, 5.3% for IHC 2+

свернуть